Daily Protocol: 1-2 mg subcutaneous injection, administered at the same time each day Alternative Protocol: 2 mg subcutaneous injection, 3 times per week Cycle Length: 12-16 weeks minimum for hair applications Break Period: 4-6 weeks between cycles Time to First Results: Subtle scalp improvements at 4-8 weeks, visible density changes at 12-16 weeks Timing considerations favor consistency above specific scheduling
No adverse effects were noted in clinical trials (ulcerative colitis, phase II) [84,85], and in toxicological studies, a lethal dose (LD1) was not achieved (for review, see [11,12,13,14,24,25])
Autocrine VEGF signaling is required for vascular homeostasis
AstraZeneca bolsters obesity pipeline with promising early data for candidates